- Open Access
HIV-1 IN/Pol recruits LEDGF/p75 into viral particles
© Desimmie et al.; licensee BioMed Central. 2015
- Received: 10 October 2014
- Accepted: 22 December 2014
- Published: 12 February 2015
The dynamic interaction between HIV and its host governs the replication of the virus and the study of the virus-host interplay is key to understand the viral lifecycle. The host factor lens epithelium-derived growth factor (LEDGF/p75) tethers the HIV preintegration complex to the chromatin through a direct interaction with integrase (IN). Small molecules that bind the LEDGF/p75 binding pocket of the HIV IN dimer (LEDGINs) block HIV replication through a multimodal mechanism impacting early and late stage replication including HIV maturation. Furthermore, LEDGF/p75 has been identified as a Pol interaction partner. This raised the question whether LEDGF/p75 besides acting as a molecular tether in the target cell, also affects late steps of HIV replication.
LEDGF/p75 is recruited into HIV-1 particles through direct interaction with the viral IN (or Pol polyprotein) and is a substrate for HIV-1 protease. Incubation in the presence of HIV-1 protease inhibitors resulted in detection of full-length LEDGF/p75 in purified viral particles. We also demonstrate that inhibition of LEDGF/p75-IN interaction by specific mutants or LEDGINs precludes incorporation of LEDGF/p75 in virions, underscoring the specificity of the uptake. LEDGF/p75 depletion did however not result in altered LEDGIN potency.
Together, these results provide evidence for an IN/Pol mediated uptake of LEDGF/p75 in viral particles and a specific cleavage by HIV protease. Understanding of the possible role of LEDGF/p75 or its cleavage fragments in the viral particle awaits further experimentation.
- Protease cleavage sites
Replication of the human immunodeficiency virus type-1 (HIV-1) is characterized by a dynamic interplay between the virus and the infected cell with a specific temporal and spatial regulation of the virus-host protein-protein interaction (PPI) network. Integration of lentiviral genomic DNA into host chromatin is directed by the viral integrase (IN) and the cellular cofactor lens epithelium-derived growth factor (LEDGF/p75) [1-5], a transcriptional co-activator that tethers a variety of proteins to the chromatin [6-10]. Whereas the N-terminal PWWP domain of LEDGF/p75 reads chromatin modifications [11-13], the C-terminal integrase binding domain (IBD) interacts with lentiviral IN ; together they direct integration into active transcription units [2,15-18]. As a molecular tether and a targeting determinant, LEDGF/p75 is recognized as a crucial cellular cofactor of HIV infection, although the related Hepatoma-derived growth factor Related-Protein 2 (HRP-2) can substitute for LEDGF/p75 in its absence [17,19,20]. Additionally, LEDGF/p75 has been shown to interact with the HIV-1 Pol precursor protein in Jurkat cells .
In 2010 structure-based drug design has led to the discovery of small molecules that bind in the LEDGF/p75 binding pocket of the IN catalytic core dimer and inhibit HIV replication , referred to as LEDGINs (small molecules binding to the LEDGF/p75 binding pocket of integrase). Similar molecules were later reported by other groups [23-27]. LEDGINs disrupt the interaction of IN with LEDGF/p75 and act as allosteric IN inhibitors. The latter mechanism of action is attributed to enhanced IN multimerization [23-25,28,29]. Unexpectedly, LEDGINs also affect late stage HIV replication [24,28,30-33], with virions produced in the presence of LEDGINs displaying severe replication defects at the level of reverse transcription (RT), nuclear import and integration [30,32,33]. Although packaging of genomic RNA and proteolytic maturation of the virus are not affected, a large proportion displays morphological defects in electron microscopy (EM) [30,32,33]. The phenotype requires the binding of LEDGINs to the LEDGF/p75 binding pocket in IN [24,30] and is mediated by enhanced multimerization of IN in the viral particles, as shown by 3 independent groups [30,32,33].
Interestingly, in a parallel approach peptides that bind LEDGF/p75 and disrupt the interaction with IN were identified by phage-display . Expression of these LEDGF/p75-interacting cyclic peptides impeded HIV replication. Mechanism of action studies revealed that the peptides block integration and reduce infectivity of virus produced in cells that constitutively express the active peptide without affecting proteolytic maturation .
Together these observations led us to hypothesize that LEDGF/p75 may be present in the viral particle, play a role in late stage replication and hence influence LEDGIN potency. Here, we present strong evidence for a specific IN (Pol)-mediated uptake of LEDGF/p75 in HIV particles and its cleavage by HIV protease. We also demonstrate that the late stage potency of LEDGINs is not affected by the presence of LEDGF/p75. Understanding of the possible role of LEDGF/p75 or its cleavage fragments in the HIV particle awaits further experimentation.
LEDGF/p75 is incorporated in HIV-1 particles and is a substrate of HIV-1 protease
Interestingly, apart from the 75 kDa band representing full-length LEDGF/p75 (Figure 1E, lane 1, closed arrowhead), smaller protein bands of different molecular weights were detected with the same anti-LEDGF/p75 antibody (Figure 1E, lane 1). Remarkably, following incubation of virus preparations with subtilisin (at 37°C for 18 h), only the smaller protein bands were detected with the same C-terminal antibody (Figure 1E, lane 2). This data suggest that the co-purified full-length LEDGF/p75 in the non-treated samples may have been a contaminant that is bound to the envelope of the virions and is partially digested by the non-specific protease subtilisin or that subtilisin may have non-specifically cleaved intravirion LEDGF/p75. Alternatively, prolonged exposure of LEDGF/p75 to HIV-1 protease (PR) in fully mature particles may have led to proteolytic cleavage of intravirion LEDGF/p75 by PR.
In order to address these issues and to verify our hypothesis, we performed a series of experiments. First, to verify the efficiency of removal of contaminating proteins and cellular debris by subtilisin treatment, we spiked virus preparations with recombinant Flag-LEDGF/p75 and performed subtilisin treatment. As expected, the exogenously added recombinant Flag-LEDGF/p75 was not detected by Flag antibody, indicating that subtilisin can completely degrade and remove any contaminating proteins from viral particles in our experimental system (Additional file 1: Figures S1A, S1B). Because exosomes and viral particles have comparable physical properties and are surrounded by a membrane, we had to rule out the contribution of cellular contaminants. After performing the same purification and sample processing, we only detected LEDGF/p75 fragments in viruses purified from MT-4 cells, a T-cell line, but not in the supernatant of uninfected control cells (Additional file 2: Figure S2), further indicating that LEDGF/p75 detected in the purified virion is not a contaminant. Second, in order to investigate the effect of subtilisin against intravirion proteins, we evaluated the level of viral proteins by Western blot analysis. The levels of IN and CA were similar with or without subtilisin treatment (Figure 1E), indicating that intravirion proteins are indeed protected from subtilisin degradation. Moreover, because subtilisin proteolysis is unaffected by ritonavir (RTV) treatment (Additional file 1: Figure S1A), the observed bands in Figure 1E (lane 2) are not proteolytic products of subtilisin treatment. Finally, we produced virus in the presence of 0.3 μM (6x IC50) RTV (PR inhibitor) and treated the purified virions with subtilisin. Full-length LEDGF/p75 was readily detected by Western blot analysis in samples treated with RTV during virus production (Figure 1E, lane 3), and was even more prominent when RTV treatment continued during purification steps too (Figure 1E, lane 4). To corroborate this, we performed Mass spectrometry analysis from RTV treated purified viruses and we were able to detect and identify LEDGF/p75 peptides (Additional file 3: Table S1, Additional file 4: Figure S3). Taken together, these observations point towards the incorporation of LEDGF/p75 in HIV particles. Furthermore, our data show that LEDGF/p75 is a substrate of HIV-1 PR irrespective of the virus producer cell lines used. Of note, only bands corresponding to IN and CA and not those of gag-products are shown to simplify the analysis. Although p24-values from virus treated with 0.3 μM RTV dropped 1 log compared to non-treated virus (as measured by 24-ELISA), we were able to detect IN and CA, since a substantial amount of virus (30 μg) was utilized for Western Blot analysis. Normalization of the virus preps was performed on protein content (BCA) and not on p24 content.
Identification of HIV-1 protease cleavage sites in LEDGF/p75
Using HIVcleave, a HIV PR cleavage prediction program , we found several predicted cleavable octapeptides in LEDGF/p75 (data not shown). We then subjected highly purified recombinant LEDGF/p75 to HIV-1 PR proteolysis. We identified and sequenced 5 prominent protein bands of HIV-1 PR-derived fragments of recombinant LEDGF/p75 (Figure 2D) and mapped the HIV-1 PR cleavage sites to the predicted cleavage sites (Figure 2D, Additional file 5: Figure S4D, Additional file 3: Tables S2 and S3). In an attempt to correlate these findings with the fragments observed in lane 2 in Figure 1E, we focused on the two small fragments below 25 kDa. Taking into account that these fragments are identified in Western blot analysis using a LEDGF/p75 specific antibody that recognizes the C-terminal end (marked in Figure 2D), the two bands below the 25 kDa marker in the second lane of Figure 1E may correspond to the 10.5 and 19.2 kDa (LEDGF357–530) fragments. Of note, none of the HIV-1 PR cleavage sites on LEDGF/p75 overlap with the described sites for caspase-3 and −7  (Additional file 3: Table S4).
LEDGF/p75 is recruited into the viral particle through interaction with HIV integrase
To further verify the specificity of LEDGF/p75 incorporation in the virions, we produced virus in the presence of LEDGIN CX05045 (10 μM), raltegravir (0.06 μM) or RTV (0.3 μM) and determined LEDGF/p75 incorporation into the virions. Less LEDGF/p75 was incorporated when virus was produced in the presence of CX05045 compared with viruses produced in the presence of DMSO, raltegravir or RTV (Figure 3D). Note, that since RTV was not present, detection of full-length LEDGF/p75 was precluded (Figure 3D, lanes 1–3). Finally, we produced NL4.3_INA128T virus, a virus resistant to CX05045, in the presence or absence of the compound, and demonstrated that CX05045 did not inhibit LEDGF/p75 incorporation into NL4.3_INA128T particles (Figure 3E), further indicating that LEDGF/p75 recruitment into HIV-1 particles is specific and depends on interaction with IN.
Finally, we estimated the ratio of LEDGF/p75 and eGFP-LEDGF325–530 to IN in the virions (Additional file 7: Figures S6A, S6B). The stoichiometry of LEDGF/p75 to IN and eGFP-LEDGF325–530 to IN were approximately 1:250 and 1:140, respectively. However, it is important to take into consideration that the effect of PR-mediated degradation of full-length LEDGF/p75 confounds this analysis leading to underestimation of the protein. Nevertheless, these results suggest that LEDGF/p75 is specifically recruited by IN and that abrogation of the LEDGF/p75-IN interaction in virus producer cells interferes with the uptake of LEDGF/p75 in the virion.
LEDGF/p75 interacts with the HIV-Pol polyprotein
Overall, on the basis of the direct interaction between HIV-1 Pol polyprotein and LEDGF/p75 in vitro, along with the requirement of IN (Pol) interaction for virion incorporation of LEDGF/p75 in the virus producer cells, we conclude that LEDGF/p75 can be specifically incorporated into the virions through an interaction with either IN or its precursor Pol protein.
LEDGIN potency is independent of the presence of LEDGF/p75 in virus producer cells
The potency of LEDGINs is not affected by the presence of LEDGF/p75 HIV producer cells
Producer cell line
EC 50 CX05045 (μM) 1
0.6 (95% CI: 0.5-0.8)
0.8 (95% CI: 0.6-1)
Together these data suggest that the recruitment of LEDGF/p75 into viral particles seems not an essential process for generation of infectious particles or late stage LEDGIN potency.
The interaction of LEDGF/p75 with HIV-1 Pol , the observations on the late stage effect of LEDGINs [24,30-33], and our data on cyclic peptides binding to LEDGF/p75 , prompted us to investigate if LEDGF/p75 is incorporated in viral particles. Our study revealed that LEDGF/p75 is indeed incorporated into HIV virions in an IN-dependent manner and that LEDGF/p75 is an authentic substrate of HIV-1 PR. We provide evidence that LEDGF/p75 already interacts with IN when part of the Pol polyprotein, probably driving the specific incorporation of LEDGF/p75 in HIV virions. Intravirion LEDGF/p75 did not alter the apparent potency of LEDGINs during late stage infection. No drastic impact of intravirion LEDGF/p75 on HIV infectivity in cell lines could be demonstrated so far.
In a series of experiments, we revealed that LEDGF/p75 can be detected in highly purified HIV virions (Figure 1), and is a substrate for HIV PR, as we detected several HIV-1 PR-derived LEDGF/p75 fragments in purified virus preparations. Addition of the PR inhibitor, RTV, allowed detection of full-length LEDGF/p75 in these virus particle preparations (Figures 1 and 2). We identified HIV PR cleavage sites for the prominent fragments using N-terminal sequencing (Figure 2, Additional file 5: Figure S4, Additional file 3: Table S3), even though multiple other sites can be identified by HIVcleave prediction. LEDGF/p75 fragments were absent or diminished in viruses containing INW131A, an IN mutant incapable of binding to LEDGF/p75, or in viruses produced from cells expressing mutant LEDGF/p75BCD366N, defective for interaction with HIV-1 IN (Figure 3). Furthermore, as PR is unlikely to be active prior to assembly to generate mature Gag and Pol products, the direct interaction between LEDGF/p75 and HIV-1 Pol (Figure 4) and the identification of LEDGF/p75 in immature virion preparations produced in presence of RTV are compatible with the requirement of a LEDGF/p75-Pol interaction for virion incorporation. We propose a model whereby LEDGF/p75 is incorporated in HIV virions through an interaction with dimeric IN core domain, already present in a Pol polyprotein dimer. Although LEDGF/p75 is a nuclear protein, it is synthesized in the cytoplasm and other examples of nuclear proteins that are detected in purified HIV particles exist. Such proteins include INI-1 , Ku70 , Ku80 and U5 small nuclear ribonucleoprotein . Moreover, although detection of LEDGF/p75 in the supernatant of cell cultures (Figure 1) may result from cell damage, LEDGF/p75 and related HRP-proteins have been shown to be secreted [46,47].
Although more than 300 human proteins have been identified in HIV viral particles (summarized in , reviewed in ), LEDGF/p75 has not been detected [36,45,48,49]. HIV protease-mediated cleavage of LEDGF/p75 might be responsible for this lack of detection. Poor avidity of the available LEDGF/p75 antibodies hampers the detection in immunoblots requiring the use of large amounts of concentrated virions. Furthermore, the low abundance of LEDGF/p75 in viral particles (Additional file 7: Figure S6) prompted us to use a specific approach for the MS analysis, focusing on part of the SDS-page gel corresponding to 75 kDa proteins for MS-analysis.
Nevertheless, taking into account the number of Pol molecules per virion, we estimate that only 1 to 2.5 molecules of LEDGF/p75 are present per viral particle. It is estimated that there are ~5,000 copies of Gag molecules per immature virion with a Gag-Pol to Gag ratio of 1:10 to 1:20. Considering 100% efficiency of proteolytic maturation of the precursor Gag-Pol and Pol polyproteins, there would be a maximum of 250 to 500 copies of RT and IN . We estimate the LEDGF/p75 to IN in the range of 1:250, estimated by semiquantitative immunoblot analysis, although PR cleavage may result in an underestimation of the absolute amount of LEDGF/p75. In any case, even though the detected intravirion LEDGF/p75 appears specifically incorporated and not the result of a contamination, only few LEDGF/p75 molecules would be present per viral particle.
Although we show that LEDGINs hamper LEDGF/p75 incorporation in the viral particle (Figure 3D), NL4.3 virus produced in LEDGF/p75KD cell lines showed a similar sensitivity to LEDGINs compared to virus produced on WT cells (Table 1). Similar results were obtained by Balakrishnan et al. , Jurado et al. , Fadel et al.  and Sharma et al. . LEDGINs do enhance IN multimerization in the absence of LEDGF/p75. Since a relatively high concentration of CX05045 (10-fold higher than for IN) seems to be required to displace LEDGF/p75 from Pol polyprotein (Figure 3C), a more subtle contribution of virion incorporated LEDGF/p75 to the mechanism of action of LEDGINs cannot be excluded.
LEDGF/p75 depletion in HIV-producer cells did not lead to aberrant morphological changes in virus particles as detected by TEM (Figure 5B,C) and no major reduction in viral infectivity (Figure 5A), as reported before .
In conclusion, we show that LEDGF/p75 is specifically recruited by IN/Pol into HIV-1 particles and that LEDGF/p75 is a substrate for HIV-1 protease. So far, no critical role can be attributed to LEDGF/p75 in the generation of infectious viral particles. Intravirion LEDGF/p75 has apparently no major effect on late stage potency of LEDGINs.
Antiviral compounds: LEDGINs (synthesized by Centre for Drug Design and Development (CD3), KULeuven R&D, Leuven, Belgium), AZT, raltegravir and RTV (obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIH).
Chemicals: subtilisin, acetylthiocholine iodide substrate and 5, 5′-dithiobis-2-nitrobenzoic acid (Ellman’s reagent, DTNB) (purchased from Sigma-Aldrich, Benelux B.V., Belgium).
Antibodies: Anti-LEDGF/p75 (rabbit, A300-848A, Bethyl laboratories, Montgomery, TX), anti-β-tubulin (mouse, T-4026, Sigma-Aldrich, St Louis, MO), anti-HIV-1 CAp24 (mouse, #24-2, AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH), anti-HIV-1 IN (mouse, IN-2 (ab66645), Abcam plc, Cambridge Science Park, Cambridge, UK or monoclonal antibody (8G4) from Division of AIDS, NIAID, NIH contributed by Dr. Dag E. Helland) and anti-Flag (mouse, M2 monoclonal antibody (F3165) Sigma-Aldrich, St. Louis, MO, USA) were used.
Cell culture and generation of cell lines
293T, and HeLa TZM-bl (obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIH: TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.) cells were maintained in Dulbecco’s modified Eagle medium (GIBCO BRL, Merelbeke, Belgium) supplemented with 8% fetal calf serum (FCS; Sigma-Aldrich, Bornem, Belgium) and 50 μg/ml gentamicin (GIBCO BRL). MT-4 and Nalm-6 cells were grown in RPMI 1640 (GIBCO BRL) supplemented with 12% FCS and 50 μg/ml gentamicin. All cell lines were grown in a humidified atmosphere with 5% CO2 at 37°C.
A SIV-based lentiviral vector (pGAE SFFV-GFP-IRES-tCD34-2xshL3mir) was used to create stable LEDGF/p75KD in 293T cells. pGAE_CAG-eGFP-WPRE  (kind gift from Didier Nègre, Ecole Normale Supérieure, Lyon) was used as backbone and digested with Esp3I and BamHI to replace the CMV early enhancer/chicken β-actin (CAG) promoter by a multiple cloning site (MCS) containing BsiWI, Eco47III and BamHI restriction sites to result in pGAE_MCS-eGFP-WPRE, which served as a backbone for further cloning. Next, eGFP was replaced by SFFV-ZeoR-IRES-tCD34-2xshL3mir, which was digested from pCH_SFFV-ZeoR-IRES-tCD34-2xshL3mir  using AgeI and ClaI and ligated into the backbone which was digested using the same restriction enzymes resulting in pGAE SFFV-ZeoR-IRES-tCD34-2xshL3mir. The SIV-based lentiviral vector was produced by transfecting 15 μg transfer plasmid, 15 μg packaging plasmid and 5 μg VSV.G envelop plasmid per culture dish carried out as described before . 293T cells were transduced at high MOI using pGAE SFFV-ZeoR-IRES-tCD34-2xshL3mir to create stable LEDGF/p75KD 293T cells. To generate 3xFlag-LEDGF/p75BC and 3xFlag-LEDGF/p75BCD366N cell lines, we transduced the LEDGF/p75KD cells with pCMHWS-3xFlag-LEDGF/p75-IRES-HygroR and pCMHWS-3xFlag-LEDGF/p75-IRES-HygroR lentiviral vectors, respectively. LEDGF/p75 expression was confirmed by immunocytochemistry, Western blot and RT-qPCR.
Virus production from LEDGF/p75 KO cells
To generate HIV+ and HIV−, 1x106 Nalm+/c and Nalm−/− cells (as described by Schrijvers et al. ) were challenged with HIV-1NL4–3 at high MOI, washed twice with PBS after two days and resuspended in culture medium; at day 7–9 the supernatant was filtered through a 0.45 μm filter (Millipore) and harvested. Three independent HIV+ and HIV− productions tested pairwise and gave reproducible results. Genotypically both viruses have WT IN as verified by sequencing.
Virus production by transfection
Production of the HIV-1 molecular clone NL4.3 was carried out by transfecting 293T cells as described before [30,53]. Briefly, 5.5 × 106 cells were plated and transfected with 20 μg of plasmid per cell culture dish in OptiMEM. The transfection mixture was added directly on the cells drop by drop. 6 h post transfection, the transfection medium was replaced with OptiMEM supplemented with 50 μg/ml gentamicin. 72 h post transfection, cell-free supernatant was harvested, filtered through 0.22 μm filters, and used directly or stored at −80°C until use.
To determine infectivity, Nalm+/c cells were infected with equal amounts of viruses normalized for p24 antigen and washed 3 times 6 hours post infection. Virus replication was monitored by quantifying p24 level in the supernatant on successive days using p24 ELISA (Innogenetics, Ghent, Belgium).
To determine the EC50 in TZM-bl cells, 2x104 cells were infected with equivalent amounts of virions produced in presence of a CX05045 1:3 dilution series. Cells were lysed in buffer containing 50 mM Tris/HCl, pH 7.3, 200 mM NaCl, 0.2% NP40 and 5% glycerol and analyzed for firefly luciferase activity (ONE-Glo™, Promega, Belgium) according to the manufacturer’s instructions. Readouts were normalized for protein content as determined by a BCA-assay (BCA Protein Assay Kit, Thermo Scientific).
Purification of HIV particles
Twenty to twenty-five 10-cm dishes of 80% confluent 293T cells were transfected with NL4.3, NL4.3_INA128T or NL4.3_INW131A as described above. For some of the experiments, RTV (300 nM) was added 6 h post transfection and added during the purification and subtilisin treatment step to prevent LEDGF/p75 cleavage by PR. At 72 h post transfection, supernatants were harvested and filtered through 0.22 μm filters (Millipore). Viruses were pelleted by ultracentrifugation (31,000 rpm, 45 minutes, Ti70 rotor, Beckman Coulter), resuspended and treated with 500 μl subtilisin (1 mg/ml) (Sigma, Belgium) in 20 mM Tris–HCl (pH 8.0), 150 mM NaCl and 1 mM CaCl2 for 18 hours at 37°C to remove any contaminating sticky proteins. Subtilisin was inactivated by adding 500 μl of DMEM supplemented with 10% FCS, 20 mM EDTA and 5 μg/ml of PMSF at room temperature for15-30 minutes. The subtilisin treated virus was then applied to an iodixanol (Optiprep™) step gradient (6–20.4%) and ultracentrifuged using the Ti70 rotor (52,000 rpm, 90 minutes). Fractions were taken from top and one-tenth of the fractions were immediately used to perform the Ellman acetylcholinesterase assay , while one-twentieth of the fractions were used for p24 ELISA to distinguish the fractions containing exosomes and pure viral particles, respectively. Fractions 8–10 were pooled, pelleted by ultracentrifugation (31,000 rpm for 45 minutes) and lysed with 1% SDS. Typical protein yields of 2–5 mg/ml were obtained and the samples were subjected to SDS-PAGE and Western blot analysis. Production of virus in MT-4 cells was achieved through infection with WT NL4.3 virus. For the purification, the same protocol was followed as for purification of virus produced in 293T cells.
Ellman acetylcholine esterase activity assay
To evaluate the virus purification procedure and in particular the separation of exosomes from virus particles, we optimized a previously described assay [35,54]. Acetylcholinesterase (AChE) hydrolyzes acetylthiocholine into thiocholine and acetate. The assay measures the activity of AChE present in intact microvesicles by quantifying the absorbance at 405 nm. 100 μl of the fractions were transferred to 96-well plates and incubated at 37°C for 10 minutes. Then 100 μl of a mixture of 100 mM sodium phosphate buffer, pH 8.0, 75 mM acetylthiocholine iodide substrate (Sigma) and 10 mM 5, 5′-dithiobis-2-nitrobenzoic acid (Ellman’s reagent, DTNB, Sigma) in a ratio of 150:2:5 was added to each well and incubated for an extra 10 minutes at 37°C. The plates were read using the Perkin Elmer Envision platform at 405 nm.
Semi-quantitative p24 ELISA
To define HIV-1 particle containing fractions and control purification efficiency, we performed a semi-quantitative p24 ELISA on the fractions using the Alliance HIV-1 p24 ELISA kit (Perkin Elmer). For this assay, we boiled 50 μl of each fraction at 95°C for 5 minutes prior to transfer to immunosorbent 96-well plates (NUNC, Denmark). After sealing the plates were incubated overnight at 4°C. Next, we removed the supernatant and blocked non-specific signal with 5% donkey serum for 30 minutes at room temperature. The subsequent experimental procedures and plate reading were performed following the manufacturer’s instructions.
In vitro HIV-1 protease (PR) assay and detection of the cleavage products
Affinity purified recombinant HIV-1 PR was a kind gift from Dr. P. Řezáčová, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic. 20 μg of purified recombinant (Flag)-LEDGF/p75 protein was incubated with 2 μg HIV-1 PR in 50 μl reaction buffer (50 mM sodium acetate buffer; pH 4.9, 200 mM NaCl and 0.002% BSA) for 2 h at 37°C. The specificity of proteolysis was controlled by incubating HIV PR with different concentrations of RTV (2.5-50 μM) for 30 minutes before adding LEDGF/p75. To monitor the order and kinetics of LEDGF/p75 proteolytic cleavage, we followed proteolysis over time and analyzed the protein bands. In all cases, PR was immediately inactivated by adding Laemmli loading buffer and heating at 98°C for 3–5 minutes and the mixtures were separated using 4-12% SDS-PAGE. Bands were visualized either by Coomassie staining or by Western blotting using anti-LEDGF/p75 (A300-848A, Bethyl Laboratories. Inc, recognizing aa 480–530) or anti-Flag antibody (detects fragments with intact N-terminus). N-terminal sequence analysis of the cleaved LEDGF/p75 derivatives was performed after blotting on PVDF membrane and staining with Coomassie brilliant blue. Individual bands were cut from the membrane, destained in methanol and the amino acid sequence was determined after elution of each band and subjected to by automated Edman degradation using a capillary 491cLC protein sequencer (Applied Biosystems).
To evaluate the effect of subtilisin on purified LEDGF/p75, 20 μg Flag-LEDGF/p75 was incubated 0, 2 or 18 hours with 13.33 ng (1:1500 enzyme to substrate ratio) or 25 μg (1:0.8 enzyme to substrate ratio) of subtilisin in 50 μl reaction buffer (20 mM Tris–HCl pH 8.0, 150 mM NaCl and 1 mM CaCl2). Inactivation and visualization was performed as described for the PR assay. To evaluate the effect of subtilisin on LEDGF/p75 absorbed to the virion surface, NL4.3 virus was pelleted, spiked during 4 hours with or without 40 μg Flag-LEDGF per 100 μL of virus and treated with or without subtilisin (1mg/mL) in subtilisin reaction buffer during 18 hours. Western blotting was performed as described above.
Purification of recombinant proteins
AlphaScreen protein-protein interaction assay
AlphaScreen (PerkinElmer) is a bead-based technology that allows studying biomolecular interactions. Briefly, all proteins, compound controls and beads were diluted to their respective working stocks in assay buffer (25 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM dithiothreitol, 1 mM MgCl2 0.1% (w/V) BSA, 0.1% (V/V) Tween 20). 5 μL buffer/compound, 5 μL GST-Pol_PRD25N and 5 μL Flag-LEDGF/p75 were added to wells of a 384-well OptiPlate (PerkinElmer). The plate was sealed and left to incubate for 1 h at 4°C. Next, 10 μL of a mix of glutathione donor and anti-Flag acceptor AlphaScreen beads was added (20 μg/mL final each), the plate was resealed and incubated for 1 more hour at 23°C. Alpha signal was read out on an EnVision Multilabel plate reader (PerkinElmer) and data were analyzed using Prism 5.0 (GraphPad).
For the titration experiments, GST-sPol_PRD25N was used at a constant concentration of 20 nM while WT and D366N Flag-LEDGF/p75 were titrated from 50 nM downward in a 1:2.5 dilution series. In the compound competition assays, both GST-Pol_PRD25N and WT Flag-LEDGF/p75 were kept constant at 20 and 5 nM respectively and CX05045, raltegravir or DMSO were titrated in a 1:2 dilution series starting at 100 μM.
5 μg Flag-tagged LEDGF/p75WT and LEDGF/p75D366N were first bound to anti-Flag M2 Affinity Gel (Sigma) and incubated 10 minutes on ice. The slurry was then incubated for 4 hours with 10μg of His-MBP- sPol_PRD25N or MBP in 250 μL binding buffer (25 mM Tris pH 7.4, 150 mM NaCl, 0.1% NP40, 1 mM MgCl2, 2 mM DTT).
After washing 3 times with wash buffer (25 mM Tris pH 7.4, 300 mM NaCl, 0.1% NP40, 1 mM MgCl2, 2 mM DTT), the proteins bound to the beads were eluted with elution buffer (binding buffer with 1% SDS) and were subjected to SDS-PAGE analysis and visualized by Coomassie staining.
Gel electrophoresis and immunoblot analysis for LEDGF/p75 uptake in virions
Protein samples were prepared in 1% SDS. Next, 30 μg of total protein content was loaded in each sample lane and proteins were separated by SDS-PAGE (4-12% bis-tris or 12.5% tris-glycine). For LEDGF/p75 and HIV-1 IN quantification a dilution series of recombinant Flag-tagged LEDGF/p75 or His-IN was loaded next to respectively 30 μg of viral lysate for LEDGF/p75 detection, 15 μg for eGFP-LEDGF325–530 detection or 7.5 μg for IN detection, purified and concentrated as described above. Protein markers were PageRuler Prestained Protein Ladder and PageRuler Prestained Protein Ladder from ThermoScientific. Proteins were detected with the respective antibody: rabbit anti-LEDGF/p75 (1:100 for viral lysate and 1:1000 for cell lysate, Bethyl Laboratories. Inc), mouse monoclonal anti-HIV-1 IN (IN2, 1:10,000 for viral lysates and 1:2000 for cell lysates, Abcam), mouse anti-HIV-1 CA (1:10,000, AIDS reagents Program). Visualization was performed using chemiluminescence (Pierce ECL, Thermo Scientific).
Negative staining EM was performed with 50 μl of inactivated virus fractions applying the grid on drop method (Laue and Bannert 2010). Four hundred mesh copper grids (Plano, Wetzlar, Germany) filmed with pioloform were coated with carbon and were glow-discharged to increase hydrophilicity and particle adherence before incubation with the virus suspension (for 10 minutes). After washing in 5 droplets of water, grids were stained with 1% phosphortungstic acid, pH 7.2 and analyzed with a TEM (Tecnai 12 BioTwin, FEI). For thin section EM. 1×106 Nalm-6 cells were infected with the NL4.3 for 2 days and then washed with PBS and incubated with fresh medium. 30 hours post washing, cells were pelleted and fixed overnight at 4°C with 2.5% glutaraldehyde. Cell pellets were post-fixed with OsO4 (1% in ddH2O; Plano, Wetzlar, Germany), block-stained with uranyl acetate (2% in ddH2O; Merck, Darmstadt, Germany), dehydrated stepwise in graded alcohol, immersed in propylenoxide and embedded in Epon (Serva, Heidelberg) with polymerisation at 60 °C for 48 h. Ultrathin sections (60–80 nm) were cut using an ultramicrotome (Ultracut S or UCT; Leica, Germany) and stained with 2% uranyl acetate and lead citrate. Transmission electron microscopy was performed with an EM 902 (Zeiss) operated at 80 kV and the images were digitised using a slow-scan charge-coupled-device camera (Pro Scan; Scheuring, Germany).
We thank Nam Joo Van der Veken, Martine Michiels, Paulien Van de Velde, Barbara Van Remoortel, Gudrun Holland and Lars Möller for excellent technical assistance. We acknowledge the Centre for Drug Design and Development (CDR) in Leuven for chemical synthesis of CX05045. BD was doctoral fellow of DBOF KU Leuven. CW, RS and JD obtained doctoral fellowships, FC is an IOF fellow of the KU Leuven. Authors declare no conflict of interests. Research at KU Leuven was funded by FWO, IAP BelVir, FP7 CHAARM, BOF IDO and OT. Research at Coda-Serva was funded by IAP-BelVir.
- Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem. 2003;278:372–81.View ArticlePubMedGoogle Scholar
- Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, et al. An essential role for LEDGF/p75 in HIV integration. Science. 2006;314:461–4.View ArticlePubMedGoogle Scholar
- Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z, et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem. 2003;278:33528–39.View ArticlePubMedGoogle Scholar
- McNeely M, Hendrix J, Busschots K, Boons E, Deleersnijder A, Gerard M, et al. In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75. J Mol Biol. 2011;410:811–30.View ArticlePubMedGoogle Scholar
- Vandekerckhove L, Christ F, Van Maele B, De Rijck J, Gijsbers R, Van den Haute C, et al. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol. 2006;80:1886–96.View ArticlePubMed CentralPubMedGoogle Scholar
- Ge H, Si Y, Roeder RG. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J. 1998;17:6723–9.View ArticlePubMed CentralPubMedGoogle Scholar
- Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008;14:36–46.View ArticlePubMed CentralPubMedGoogle Scholar
- Daugaard M, Baude A, Fugger K, Povlsen LK, Beck H, Sorensen CS, et al. LEDGF (p75) promotes DNA-end resection and homologous recombination. Nat Struct Mol Biol. 2012;19:803–10.View ArticlePubMedGoogle Scholar
- Bartholomeeusen K, De Rijck J, Busschots K, Desender L, Gijsbers R, Emiliani S, et al. Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75. J Mol Biol. 2007;372:407–21.View ArticlePubMedGoogle Scholar
- Maertens GN, Cherepanov P, Engelman A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J Cell Sci. 2006;119:2563–71.View ArticlePubMedGoogle Scholar
- Shun MC, Botbol Y, Li X, Di Nunzio F, Daigle JE, Yan N, et al. Identification and characterization of PWWP domain residues critical for LEDGF/p75 chromatin binding and human immunodeficiency virus type 1 infectivity. J Virol. 2008;82:11555–67.View ArticlePubMed CentralPubMedGoogle Scholar
- Gijsbers R, Vets S, De Rijck J, Ocwieja KE, Ronen K, Malani N, et al. Role of the PWWP domain of lens epithelium-derived growth factor (LEDGF)/p75 cofactor in lentiviral integration targeting. J Biol Chem. 2011;286:41812–25.View ArticlePubMed CentralPubMedGoogle Scholar
- Pradeepa MM, Sutherland HG, Ule J, Grimes GR, Bickmore WA. Psip1/Ledgf p52 binds methylated histone H3K36 and splicing factors and contributes to the regulation of alternative splicing. PLoS Genet. 2012;8:e1002717.View ArticlePubMed CentralPubMedGoogle Scholar
- Cherepanov P, Devroe E, Silver PA, Engelman A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem. 2004;279:48883–92.View ArticlePubMedGoogle Scholar
- Shun MC, Raghavendra NK, Vandegraaff N, Daigle JE, Hughes S, Kellam P, et al. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 2007;21:1767–78.View ArticlePubMed CentralPubMedGoogle Scholar
- Hendrix J, Gijsbers R, De Rijck J, Voet A, Hotta J, McNeely M, et al. The transcriptional co-activator LEDGF/p75 displays a dynamic scan-and-lock mechanism for chromatin tethering. Nucleic Acids Res. 2011;39:1310–25.View ArticlePubMed CentralPubMedGoogle Scholar
- Schrijvers R, De Rijck J, Demeulemeester J, Adachi N, Vets S, Ronen K, et al. LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog. 2012;8:e1002558.View ArticlePubMed CentralPubMedGoogle Scholar
- Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P, et al. A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med. 2005;11:1287–9.View ArticlePubMedGoogle Scholar
- Schrijvers R, Vets S, De Rijck J, Malani N, Bushman FD, Debyser Z, et al. HRP-2 determines HIV-1 integration site selection in LEDGF/p75 depleted cells. Retrovirology. 2012;9:84.View ArticlePubMed CentralPubMedGoogle Scholar
- Wang H, Jurado KA, Wu XL, Shun MC, Li X, Ferris AL, et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res. 2012;40:11518–30.View ArticlePubMed CentralPubMedGoogle Scholar
- Jager S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, et al. Global landscape of HIV-human protein complexes. Nature. 2012;481:365–70.Google Scholar
- Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol. 2010;6:442–8.View ArticlePubMedGoogle Scholar
- Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, et al. Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors. J Biol Chem. 2012;287:16801–11.View ArticlePubMed CentralPubMedGoogle Scholar
- Le Rouzic E, Bonnard D, Chasset S, Bruneau JM, Chevreuil F, Le Strat F, et al. Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. Retrovirology. 2013;10:144.View ArticlePubMed CentralPubMedGoogle Scholar
- Tsiang M, Jones GS, Niedziela-Majka A, Kan E, Lansdon EB, Huang W, et al. New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action. J Biol Chem. 2012;287:21189–203.View ArticlePubMed CentralPubMedGoogle Scholar
- Sharma A, Slaughter A, Jena N, Feng L, Kessl JJ, Fadel HJ, et al. A new class of multimerization selective inhibitors of HIV-1 integrase. PLoS Pathog. 2014;10:e1004171.View ArticlePubMed CentralPubMedGoogle Scholar
- Gupta K, Brady T, Dyer BM, Malani N, Hwang Y, Male F, et al. Allosteric inhibition of human immunodeficiency virus integrase: Late block during viral replication and abnormal multimerization involving specific protein domains. J Biol Chem. 2014;289:20477–88.View ArticlePubMedGoogle Scholar
- Christ F, Shaw S, Demeulemeester J, Desimmie BA, Marchand A, Butler S, et al. Small molecule inhibitors of the LEDGF/p75 binding site of integrase (LEDGINs) block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother. 2012. In Press: doi:10.1128/AAC.00717-00712.Google Scholar
- Demeulemeester J, Tintori C, Botta M, Debyser Z, Christ F. Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. J Biomol Screen. 2012;17:618–28.View ArticlePubMedGoogle Scholar
- Desimmie BA, Schrijvers R, Demeulemeester J, Borrenberghs D, Weydert C, Thys W, et al. LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology. 2013;10:57.View ArticlePubMed CentralPubMedGoogle Scholar
- Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, et al. The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem. 2013;288:15813–20.View ArticlePubMed CentralPubMedGoogle Scholar
- Jurado KA, Wang H, Slaughter A, Feng L, Kessl JJ, Koh Y, et al. Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci U S A. 2013;110:8690–5.View ArticlePubMed CentralPubMedGoogle Scholar
- Balakrishnan M, Yant SR, Tsai L, O'Sullivan C, Bam RA, Tsai A, et al. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One. 2013;8:e74163.View ArticlePubMed CentralPubMedGoogle Scholar
- Desimmie BA, Humbert M, Lescrinier E, Hendrix J, Vets S, Gijsbers R, et al. Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication. Mol Ther. 2012;20:2064–75.View ArticlePubMed CentralPubMedGoogle Scholar
- Cantin R, Diou J, Belanger D, Tremblay AM, Gilbert C. Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. J Immunol Methods. 2008;338:21–30.View ArticlePubMedGoogle Scholar
- Ott DE. Cellular proteins detected in HIV-1. Rev Med Virol. 2008;18:159–75.View ArticlePubMedGoogle Scholar
- Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969;244:4406–12.PubMedGoogle Scholar
- HIVcleave. [http://www.csbio.sjtu.edu.cn/bioinf/HIV/#]
- Wu X, Daniels T, Molinaro C, Lilly MB, Casiano CA. Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogates its pro-survival function: implications for autoimmunity in atopic disorders. Cell Death Differ. 2002;9:915–25.View ArticlePubMedGoogle Scholar
- Busschots K, Voet A, De Maeyer M, Rain JC, Emiliani S, Benarous R, et al. Identification of the LEDGF/p75 binding site in HIV-1 integrase. J Mol Biol. 2007;365:1480–92.View ArticlePubMedGoogle Scholar
- Cherepanov P, Ambrosio AL, Rahman S, Ellenberger T, Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci U S A. 2005;102:17308–13.View ArticlePubMed CentralPubMedGoogle Scholar
- Fadel HJ, Morrison JH, Saenz DT, Fuchs JR, Kvaratskhelia M, Ekker SC, et al. TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism. J Virol. 2014;88:9704–17.View ArticlePubMed CentralPubMedGoogle Scholar
- Yung E, Sorin M, Wang EJ, Perumal S, Ott D, Kalpana GV. Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance. J Virol. 2004;78:2222–31.View ArticlePubMed CentralPubMedGoogle Scholar
- Zheng Y, Ao Z, Wang B, Jayappa KD, Yao X. Host protein Ku70 binds and protects HIV-1 integrase from proteasomal degradation and is required for HIV replication. J Biol Chem. 2011;286:17722–35.View ArticlePubMed CentralPubMedGoogle Scholar
- Santos S, Obukhov Y, Nekhai S, Bukrinsky M, Iordanskiy S. Virus-producing cells determine the host protein profiles of HIV-1 virion cores. Retrovirology. 2012;9:65.View ArticlePubMed CentralPubMedGoogle Scholar
- Singh DP, Ohguro N, Kikuchi T, Sueno T, Reddy VN, Yuge K, et al. Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts. Biochem Biophys Res Commun. 2000;267:373–81.View ArticlePubMedGoogle Scholar
- Thirant C, Galan-Moya EM, Dubois LG, Pinte S, Chafey P, Broussard C, et al. Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells. 2012;30:845–53.View ArticlePubMedGoogle Scholar
- AVP Protein Database. [http://ncifrederick.cancer.gov/research/avp/protein_db.asp]
- Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess Jr JW, et al. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol. 2006;80:9039–52.View ArticlePubMed CentralPubMedGoogle Scholar
- Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, Vogt VM, et al. The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol. 2004;11:672–5.View ArticlePubMedGoogle Scholar
- Mangeot PE, Duperrier K, Negre D, Boson B, Rigal D, Cosset FL, et al. High levels of transduction of human dendritic cells with optimized SIV vectors. Mole Therapy J Am Soc Gene Therapy. 2002;5:283–90.View ArticleGoogle Scholar
- Vets S, Kimpel J, Volk A, De Rijck J, Schrijvers R, Verbinnen B, et al. Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model. Mole Therapy J Am Soc Gene Therapy. 2012;20:908–17.View ArticleGoogle Scholar
- Geraerts M, Michiels M, Baekelandt V, Debyser Z, Gijsbers R. Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med. 2005;7:1299–310.View ArticlePubMedGoogle Scholar
- Ellman GL, Courtney KD, Andres Jr V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88–95.View ArticlePubMedGoogle Scholar
- Shen HB, Chou KC. HIVcleave: a web-server for predicting human immunodeficiency virus protease cleavage sites in proteins. Anal Biochem. 2008;375:388–90.View ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.